FBRX – Forte Biosciences Inc
Float Short %
4.7
Margin Of Safety %
Put/Call OI Ratio
0.77
EPS Next Q Diff
0.01
EPS Last/This Y
7.85
EPS This/Next Y
0.53
Price
31.74
Target Price
63.75
Analyst Recom
1
Performance Q
173.58
Relative Volume
2.78
Beta
3.21
Ticker: FBRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | FBRX | 27.78 | 0.72 | 0.00 | 542 |
| 2025-12-29 | FBRX | 26.03 | 0.72 | 0.00 | 542 |
| 2025-12-30 | FBRX | 26.26 | 0.72 | 0.00 | 542 |
| 2025-12-31 | FBRX | 27.65 | 0.72 | 0.00 | 542 |
| 2026-01-02 | FBRX | 23.64 | 0.72 | 0.00 | 542 |
| 2026-01-05 | FBRX | 22.54 | 0.72 | 0.00 | 543 |
| 2026-01-06 | FBRX | 23.61 | 0.72 | 0.00 | 543 |
| 2026-01-07 | FBRX | 26.06 | 0.72 | 0.00 | 543 |
| 2026-01-08 | FBRX | 24.24 | 0.72 | 0.00 | 543 |
| 2026-01-09 | FBRX | 23.87 | 0.72 | 0.00 | 543 |
| 2026-01-12 | FBRX | 29.41 | 0.72 | 5.33 | 546 |
| 2026-01-13 | FBRX | 32.47 | 0.76 | 0.14 | 563 |
| 2026-01-14 | FBRX | 32.48 | 0.76 | 0.00 | 569 |
| 2026-01-15 | FBRX | 32.81 | 0.75 | 0.00 | 573 |
| 2026-01-16 | FBRX | 33.47 | 0.74 | 0.00 | 575 |
| 2026-01-20 | FBRX | 30.43 | 0.77 | 0.67 | 541 |
| 2026-01-21 | FBRX | 31.38 | 0.78 | 0.00 | 544 |
| 2026-01-22 | FBRX | 31.88 | 0.78 | 0.00 | 544 |
| 2026-01-23 | FBRX | 31.26 | 0.77 | 0.00 | 547 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | FBRX | 27.72 | - | - | -4.32 |
| 2025-12-29 | FBRX | 26.07 | - | - | -4.32 |
| 2025-12-30 | FBRX | 25.93 | - | - | -4.32 |
| 2025-12-31 | FBRX | 27.61 | - | - | -4.32 |
| 2026-01-02 | FBRX | 23.68 | - | - | -4.32 |
| 2026-01-05 | FBRX | 22.50 | - | - | -4.32 |
| 2026-01-06 | FBRX | 23.62 | - | - | -4.32 |
| 2026-01-07 | FBRX | 26.28 | - | - | -4.32 |
| 2026-01-08 | FBRX | 24.22 | - | - | -4.32 |
| 2026-01-09 | FBRX | 23.76 | - | - | -4.32 |
| 2026-01-12 | FBRX | 29.66 | - | - | -4.32 |
| 2026-01-13 | FBRX | 32.35 | - | - | -4.32 |
| 2026-01-14 | FBRX | 32.35 | - | - | -4.32 |
| 2026-01-15 | FBRX | 32.72 | - | - | -4.32 |
| 2026-01-16 | FBRX | 33.53 | - | - | -4.32 |
| 2026-01-20 | FBRX | 30.46 | - | - | -4.32 |
| 2026-01-21 | FBRX | 31.44 | - | - | -4.32 |
| 2026-01-22 | FBRX | 31.95 | - | - | -4.32 |
| 2026-01-23 | FBRX | 31.74 | - | - | -4.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | FBRX | 0.00 | 2.37 | 1.30 |
| 2025-12-29 | FBRX | 0.00 | 10.57 | 1.30 |
| 2025-12-30 | FBRX | 0.00 | 10.57 | 1.30 |
| 2025-12-31 | FBRX | 0.00 | 10.57 | 1.30 |
| 2026-01-02 | FBRX | 0.54 | 10.57 | 1.30 |
| 2026-01-05 | FBRX | 0.54 | 10.57 | 1.30 |
| 2026-01-06 | FBRX | 0.54 | 10.57 | 1.30 |
| 2026-01-07 | FBRX | 0.54 | 10.57 | 1.30 |
| 2026-01-08 | FBRX | 0.54 | 10.57 | 1.30 |
| 2026-01-09 | FBRX | 0.54 | 10.57 | 1.30 |
| 2026-01-12 | FBRX | 0.53 | 10.58 | 1.30 |
| 2026-01-13 | FBRX | 0.53 | 10.58 | 4.78 |
| 2026-01-14 | FBRX | 0.53 | 10.58 | 4.78 |
| 2026-01-15 | FBRX | 0.53 | 10.58 | 4.70 |
| 2026-01-16 | FBRX | 0.59 | 10.58 | 4.70 |
| 2026-01-20 | FBRX | 0.59 | 10.45 | 4.70 |
| 2026-01-21 | FBRX | 0.59 | 10.45 | 4.70 |
| 2026-01-22 | FBRX | 0.59 | 10.45 | 4.70 |
| 2026-01-23 | FBRX | 0.59 | 10.45 | 4.70 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.99
Avg. EPS Est. Current Quarter
-1.18
Avg. EPS Est. Next Quarter
-0.98
Insider Transactions
0.59
Institutional Transactions
10.45
Beta
3.21
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
8
Growth Score
19
Sentiment Score
74
Actual DrawDown %
97.1
Max Drawdown 5-Year %
-99.6
Target Price
63.75
P/E
Forward P/E
PEG
P/S
P/B
4.75
P/Free Cash Flow
EPS
-4.44
Average EPS Est. Cur. Y
-4.32
EPS Next Y. (Est.)
-3.78
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
2.78
Return on Equity vs Sector %
-88.8
Return on Equity vs Industry %
-72.8
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.12
EBIT Estimation
Forte Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 16
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
stock quote shares FBRX – Forte Biosciences Inc Stock Price stock today
news today FBRX – Forte Biosciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FBRX – Forte Biosciences Inc yahoo finance google finance
stock history FBRX – Forte Biosciences Inc invest stock market
stock prices FBRX premarket after hours
ticker FBRX fair value insiders trading